Bioqual

Bioqual Liabilities

The The Liabilities of Bioqual (BIOQ) as of Sep 26, 2026 is 36.04 M USD. In the previous year, The Liabilities was 20.96 M USD — a change of 71.90% (higher).

Liabilities

36.04 MUSD

YoY

71.90%

Last updated:

In 2026, Bioqual's total liabilities amounted to 36.04 M USD, a 71.90% difference from the 20.96 M USD total liabilities in the previous year.

The Bioqual Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
3.75 M USD
Jan 1, 2020
21.37 M USD
Jan 1, 2021
19.89 M USD
Jan 1, 2022
25.67 M USD
Jan 1, 2023
23.70 M USD
Jan 1, 2024
18.94 M USD
Jan 1, 2025
20.96 M USD
Jan 1, 2026
36.04 M USD
The Bioqual Liabilities history
YEARLiabilitiesYoY
36.04 MUSD+71.90%
20.96 MUSD+10.70%
18.94 MUSD-20.10%
23.70 MUSD-7.66%
25.67 MUSD+29.06%
19.89 MUSD-6.91%
21.37 MUSD+470.44%
3.75 MUSD-11.98%
4.26 MUSD+10.68%
3.84 MUSD-5.61%
4.07 MUSD-10.95%
4.57 MUSD+3.60%
4.42 MUSD—
Access this data via the Eulerpool API

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Bioqual's Liabilities

Bioqual's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bioqual's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bioqual's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bioqual's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bioqual’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bioqual stock

The Liabilities of Bioqual is 36.04 M USD in 2026.

The Liabilities of Bioqual changed from 20.96 M USD to 36.04 M USD, representing a 71.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Bioqual since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Bioqual historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bioqual

All Key Metrics — Bioqual